YOLT-101
Another single-infusion #BaseEditor therapy for Heterozygous Familial Hypercholesterolemia
From #YolTech Therapeutics
0.6 mg/kg N=3
Being effective in 1 wk
Sustained 70% ⬇️plasma PCSk9 & 50% ⬇️LDL-C till 16-wk
medRxiv 2025
www.medrxiv.org/content/10.1...
4
0
0
0